Developmental Study on Fatigue in Cancer

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

L-carnitine is a supplement (type of vitamin) that has been suggested to be decreased in patients with cancer. We will identify patients that have terminal cancer and fatigue. The purpose of this study is to determine if L-carnitine replacement improves fatigue in cancer patients with L-carnitine deficiency.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)
• Collaborators: National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID)

Criteria

Inclusion:

• Patients with diagnosis of cancer and estimated life expectancy of less than 6 months.

• Patients who have undergone antineoplastic therapy which may worsen fatigue or promote carnitine deficiency will be eligible if completed the therapy more than 90 days prior to beginning the study.

Exclusion:

• Uncontrolled or severe cardiovascular, pulmonary, or renal disease.

• Patients with encephalopathy or psychiatric disorder sufficiently severe to impair completion of the questionnaire.

• Treatment or replacement therapy with any form of carnitine less than 12 months prior to enrollment.

• Known sensitivity to carnitine.

• History of seizures or stroke.